Targeting Toll-like receptors: emerging therapeutics?

Related Experiment Video

Updated: Jun 14, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

Elizabeth J Hennessy1, Andrew E Parker, Luke A J O'Neill

  • 1Trinity College Dublin,School of Biochemistry and Immunology, Dublin 2, Ireland.

Nature Reviews. Drug Discovery
|April 10, 2010
PubMed

Insights

Targeting Toll-like receptors (TLRs) shows promise for treating cancer and inflammatory diseases. Research focuses on TLR7 and TLR9 activators and inhibitors, with new signaling insights offering therapeutic potential.

Area of Science:

  • Immunology
  • Pharmacology
  • Drug Discovery

Background:

  • Growing interest in targeting Toll-like receptors (TLRs) for various diseases.
  • TLRs play crucial roles in immune responses and disease pathogenesis.
  • Existing research focuses on specific TLRs for therapeutic interventions.

Purpose of the Study:

  • To review TLRs with the most promise for drug discovery.
  • To highlight agents in discovery and clinical trials.
  • To explore emerging aspects of TLR-mediated signaling for therapeutic manipulation.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Focus on TLR7 and TLR9 activators and inhibitors.
  • Examination of novel signaling pathways like ubiquitination and microRNAs.

Main Results:

  • Several compounds targeting TLRs are in preclinical and clinical evaluation.
  • TLR7 and TLR9 activators are explored as adjuvants for infection and cancer.
  • TLR2, TLR4, TLR7, and TLR9 inhibitors are investigated for sepsis and inflammatory diseases.

Conclusions:

  • Targeting TLRs offers significant therapeutic potential for cancer and inflammatory conditions.
  • Emerging insights into TLR signaling, including ubiquitination and microRNAs, present new avenues for drug development.
  • Continued research into TLR modulation is crucial for advancing treatment strategies.

More Related Videos

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces07:55

A Macrophage Reporter Cell Assay to Examine Toll-Like Receptor-Mediated NF-kB/AP-1 Signaling on Adsorbed Protein Layers on Polymeric Surfaces

Published on: January 7, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.